Spruce smartens up pipeline with deal for BioMarin asset, plans 2026 approval filing

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans to seek accelerated FDA approval in the first half of next year.